Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma

Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. This randomized, placebo-controlled clinical trial showed a reduction in the annualized rate of asthma exacerbations among patients with severe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-05, Vol.384 (19), p.1800-1809
Hauptverfasser:	Menzies-Gow, Andrew, Corren, Jonathan, Bourdin, Arnaud, Chupp, Geoffrey, Israel, Elliot, Wechsler, Michael E, Brightling, Christopher E, Griffiths, Janet M, Hellqvist, Åsa, Bowen, Karin, Kaur, Primal, Almqvist, Gun, Ponnarambil, Sandhia, Colice, Gene
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Adverse events Age Aged Aged, 80 and over Airway management Allergology Anti-Asthmatic Agents / adverse effects Anti-Asthmatic Agents / therapeutic use Antibodies, Monoclonal, Humanized / adverse effects Asthma Biomarkers Cytokines Hospitalization Human health and pathology Immunology Immunotherapy Inflammation Informed consent Leukocytes (eosinophilic) Life Sciences Monoclonal antibodies Patients Placebos Pulmonology and respiratory tract Quality of life Questionnaires Respiratory function Statistical analysis Teenagers Thymic stromal lymphopoietin Thymus
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. This randomized, placebo-controlled clinical trial showed a reduction in the annualized rate of asthma exacerbations among patients with severe, uncontrolled asthma treated with tezepelumab.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2034975